

Supplementary Table 1. Patient characteristics.

Group	Female	Age at biopsy	Dermatomyositis	Infl. infiltrates	Type of tumor	Treat. cycle	PD1 inhibitor	PD-L1 inhibitor	CTLA4 inhibitor	Myocarditis	Diplopia	Dysphagia	Anti-striational	Anti-AChR	Other abts	CK at biopsy	Peak CK
ICL_DM	no	73	yes	yes	Urothelial carcinoma	2	yes	no	no	no	no	no	NA	NA	Anti-TIF1g	428	428
ICL_DM	no	44	yes	yes	Melanoma	1	yes	no	no	no	no	no	NA	NA	Anti-TIF1g	9088	9088
ICL_DM	yes	75	yes	yes	Urothelial carcinoma	2	no	yes	no	no	no	no	NA	NA	Anti-TIF1g	129	129
ICL_MY01	no	63	no	yes	Pancreatic adenocarcinoma	1	no	yes	no	yes	yes	no	NA	yes	Anti-Ro60, anti-Ro52, anti-SRP, anti-Mi2a	2889	4204
ICL_MY01	no	69	no	yes	Liposarcoma	1	yes	no	no	no	no	no	yes	yes	Anti-MuSK	172	14000
ICL_MY01	no	72	no	yes	Thyroid anaplastic	1	no	yes	yes	yes	yes	no	yes	no	Anti-Ic1	912	23495
ICL_MY01	no	65	no	yes	Pancreatic neuroendocrine	2	no	yes	yes	no	yes	no	yes	yes	Anti-SRP	273	2430
ICL_MY01	no	82	no	yes	Melanoma	1	yes	no	no	yes	no	no	yes	yes	NA	85	85
ICL_MY01	no	60	no	yes	Squamous cell lung carcinoma	3	no	yes	no	no	no	no	yes	yes	None	201	201
ICL_MY01	no	74	no	yes	Thymoma	4	no	yes	no	no	no	no	yes	no	Anti-PM/Sc1100	597	1150
ICL_MY01	no	63	no	yes	Squamous cell lung carcinoma	3	yes	no	no	no	yes	no	no	no	Anti-TIF1g, anti-Ro52	380	380
ICL_MY01	yes	61	no	yes	Squamous head neck carcinoma	3	yes	no	no	no	no	no	no	no	Anti-HMGR	1900	5976
ICL_MY01	no	86	no	yes	Cholangiocarcinoma	2	no	yes	no	yes	no	no	yes	yes	Anti-TIF1g	638	11953
ICL_MY01	no	67	no	yes	Lung adenocarcinoma	2	yes	no	no	yes	no	yes	yes	no	Anti-PM/Sc1, anti-M2	10850	10850
ICL_MY01	yes	62	no	yes	Breast adenocarcinoma	1	yes	no	no	yes	yes	no	yes	yes	None	11830	11830
ICL_MY01	yes	60	no	yes	Melanoma	1	yes	no	no	no	no	no	no	NA	Anti-Mi2	1154	1154
ICL_MY01	yes	66	no	yes	Lung adenocarcinoma	2	yes	no	no	yes	no	no	yes	yes	Anti-NPX2, anti-Ro52	1934	1934
ICL_MY01	yes	58	no	yes	Melanoma	3	yes	no	no	no	no	no	NA	NA	None	666	666
ICL_MY01	yes	81	no	yes	Melanoma	1	yes	no	no	yes	no	no	no	no	Anti-NTSc1A	8333	8333
ICL_MY01	no	55	no	no	Melanoma	2	yes	no	no	yes	no	no	no	no	NA	280	1284
ICL_MY01	no	57	no	yes	Melanoma	2	yes	no	no	no	no	no	yes	no	NA	180	444
ICL_MY01	no	49	no	yes	Esophageal adenocarcinoma	2	yes	no	no	yes	yes	no	no	no	NA	180	333
ICL_MY01	no	84	no	no	Merkel cell carcinoma	1	yes	no	no	no	no	yes	yes	yes	None	1226	2685
ICL_MY01	no	78	no	no	Thymoma	1	no	yes	no	yes	no	no	NA	yes	None	1195	1195
ICL_MY01	yes	68	no	yes	Thymoma	1	no	yes	no	yes	no	no	NA	yes	None	977	977
ICL_MY01	yes	59	no	NA	Thymoma	2	no	yes	no	no	no	no	NA	no	None	1086	1086
ICL_MY01	no	50	no	NA	Thymoma	1	no	yes	no	yes	no	no	NA	yes	None	880	1084
ICL_MY02	no	76	no	yes	Melanoma	2	yes	no	no	no	no	no	NA	yes	Anti-Mi2b, anti-NXP2	1169	4275
ICL_MY02	yes	65	no	no	Mesothelioma	3	yes	no	no	no	no	no	NA	NA	NA	51	481
ICL_MY02	no	69	no	no	Pancreatic adenocarcinoma	1	yes	no	yes	no	no	no	NA	NA	NA	5599	6260
ICL_MY02	no	69	no	no	Melanoma	1	yes	no	no	no	no	no	yes	no	NA	427	7307
ICL_MY02	no	46	no	no	Follicular lymphoma	2	yes	no	no	no	yes	no	yes	yes	NA	72	72
ICL_MY02	no	70	no	yes	Melanoma	1	yes	no	no	no	no	yes	yes	no	None	NA	542
ICL_MY02	yes	88	no	no	Renal cell carcinoma	2	yes	no	yes	no	no	yes	no	no	None	26	28
ICL_MY02	no	68	no	yes	Renal cell carcinoma	1	yes	no	yes	no	no	no	yes	no	NA	492	762

Supplementary Table 2. Type of immune checkpoint inhibitor.

Group	Nivolumab	Pembrolizumab	Atezolizumab	Avelumab	Durvalumab	Tremelimumab	Ipilimumab	M7824
ICI_DM	no	yes	no	no	no	no	no	no
ICI_DM	yes	no	no	no	no	no	no	no
ICI_DM	no	no	no	yes	no	no	no	no
ICI_MY01	no	no	yes	no	no	no	no	no
ICI_MY01	no	yes	no	no	no	no	no	no
ICI_MY01	no	no	no	no	yes	yes	no	no
ICI_MY01	no	no	no	no	yes	yes	no	no
ICI_MY01	no	yes	no	no	no	no	no	no
ICI_MY01	no	no	no	no	yes	no	no	no
ICI_MY01	no	no	yes	no	no	no	no	no
ICI_MY01	yes	no	no	no	no	no	no	no
ICI_MY01	no	yes	no	no	no	no	no	no
ICI_MY01	no	no	no	no	no	no	no	yes
ICI_MY01	no	yes	no	no	no	no	no	no
ICI_MY01	no	yes	no	no	no	no	no	no
ICI_MY01	yes	no	no	no	no	no	no	no
ICI_MY01	no	yes	no	no	no	no	no	no
ICI_MY01	yes	no	no	no	no	no	no	no
ICI_MY01	yes	no	no	no	no	no	no	no
ICI_MY01	yes	no	no	no	no	no	no	no
ICI_MY01	no	yes	no	no	no	no	no	no
ICI_MY01	no	yes	no	no	no	no	no	no
ICI_MY01	no	yes	no	no	no	no	no	no
ICI_MY01	no	no	no	yes	no	no	no	no
ICI_MY01	no	no	no	yes	no	no	no	no
ICI_MY01	no	no	no	yes	no	no	no	no
ICI_MY01	no	no	no	yes	no	no	no	no
ICI_MY01	no	no	no	yes	no	no	no	no
ICI_MY02	no	yes	no	no	no	no	no	no
ICI_MY02	no	yes	no	no	no	no	no	no
ICI_MY02	yes	no	no	no	no	no	yes	no
ICI_MY02	no	yes	no	no	no	no	no	no
ICI_MY02	no	yes	no	no	no	no	no	no
ICI_MY02	yes	no	no	no	no	no	no	no
ICI_MY02	yes	no	no	no	no	no	yes	no
ICI_MY02	yes	no	no	no	no	no	yes	no

Supplementary Table 3. Differential expression of relevant genes related to immune-checkpoint inhibitor myopathy by bulk RNA sequencing. The different groups identified by the unsupervised clustering analysis (ICI-DM, ICI-MYO1, and ICI-MYO2) were compared to normal muscle biopsies (NT) and to each other. Missing values correspond to genes that did not pass the cutoff to be included in the differential expression.

Gene	ICI-MYO1 vs. NT		ICI-MYO2 vs. NT		ICI-DM vs. NT		ICI-MYO1 vs. ICI-MYO2		ICI-DM vs. ICI-MYO1		ICI-DM vs. ICI-MYO2	
	logFC	adj.P.Val	logFC	adj.P.Val	logFC	adj.P.Val	logFC	adj.P.Val	logFC	adj.P.Val	logFC	adj.P.Val
	ACTA1	-2.2	5e-08	-0.8	2e-05	-3.4	7e-16	-1.3	0.1	-1.2	0.6	-2.6
BDNF	-1.1	0.07	0.1	0.9	0.3	0.8	-1.3	0.07	1.5	0.3	0.1	0.9
CAMLG	-0.0	0.6	0.2	0.1	-0.0	1	-0.2	0.1	0.1	0.9	-0.2	0.3
CD14	2.3	1e-07	-0.7	0.05	1.9	2e-05	3.0	0.002	-0.5	0.8	2.5	9e-04
CD19		NA		NA		NA	2.5	0.007	-0.0	1		NA
CD27	2.8	1e-05		NA	1.4	0.03	3.2	0.008	-1.5	0.6	1.7	0.2
CD274	-0.3	0.4	-0.9	0.004	1.5	6e-06	0.5	0.6	1.9	0.1	2.3	0.003
CD3E	1.9	0.01	-0.4	0.5	1.8	0.001	2.2	0.2	-0.2	1	2.0	0.1
CD4	2.8	2e-11	-0.7	0.06	1.5	8e-04	3.5	2e-04	-1.2	0.3	2.2	0.01
CD40	0.9	8e-08	0.3	0.03	0.7	4e-04	0.6	0.04	-0.2	0.8	0.4	0.2
CD40LG		NA		NA	0.4	0.7	2.7	0.02	0.0	1		NA
CD68	3.1	1e-08	0.5	0.2	3.7	1e-09	2.5	0.01	0.6	0.8	3.1	0.001
CD70		NA		NA	1.5	0.06	3.0	0.002	-0.5	0.8		NA
CD80		NA		NA		NA	2.2	0.02	2.2	0.04	4.4	0.002
CD86	3.1	1e-06	-0.2	0.7	3.1	5e-10	3.2	0.007	0.1	1	3.2	0.002
CD8A	3.5	8e-06	0.5	0.3	2.4	6e-05	3.0	0.03	-1.2	0.7	1.7	0.2
CEBPB	0.8	5e-04	1.4	1e-04	1.0	0.05	-0.6	0.2	0.2	0.9	-0.5	0.4
COX7B	-1.2	1e-14	-0.7	2e-04	-1.7	7e-09	-0.6	0.04	-0.4	0.5	-1.1	0.02
COX7C	-0.9	1e-12	-0.3	0.05	-1.2	7e-06	-0.6	0.006	-0.3	0.6	-0.9	0.006
CTLA4		NA		NA		NA	3.2	0.04	-1.2	0.7	2.0	0.2
EDA	0.2	0.5	-0.4	0.05	-0.7	0.007	0.5	0.3	-0.8	0.4	-0.4	0.5
EDA2R	0.9	0.005	0.1	0.9	1.5	0.001	0.8	0.2	0.7	0.5	1.5	0.1
EGR1	2.8	2e-05	0.1	0.9	3.2	0.01	2.7	0.01	0.2	1	3.0	0.03
FAS	0.8	2e-04	-0.2	0.5	1.5	2e-06	0.9	0.02	0.8	0.2	1.7	0.003
FASLG		NA		NA	2.7	6e-05	2.5	0.05	0.1	1	2.7	0.006
FOS	3.5	9e-06	0.7	0.5	3.6	0.02	2.9	0.01	-0.0	1	2.8	0.05
FOSB	4.6	4e-06	1.0	0.2	3.5	5e-04	3.8	0.03	-1.3	0.7	2.6	0.05
FOSL1	4.2	2e-08	1.4	0.006	5.8	7e-15	2.7	0.005	1.7	0.1	4.3	4e-07
GBP2	2.5	1e-13	1.2	6e-06	3.0	1e-11	1.3	0.04	0.5	0.8	1.8	0.01
GZMA	2.3	0.004	-0.3	0.5	1.9	4e-04	2.4	0.1	-0.5	0.9	2.0	0.08
GZMB	2.7	0.009	0.4	0.5	3.7	3e-09	2.2	0.2	1.0	0.8	3.1	0.004
ICAM1	2.3	4e-13	0.1	0.8	2.5	1e-10	2.2	2e-04	0.2	0.9	2.4	7e-04
IFI30	5.0	4e-13	0.4	0.7	5.2	2e-10	4.6	9e-04	0.2	0.9	4.7	0.02
IFNA1		NA		NA		NA		NA		NA		NA
IFNA10		NA		NA		NA		NA		NA		NA
IFNA13		NA		NA		NA		NA		NA		NA
IFNA14		NA		NA		NA		NA		NA		NA
IFNA16		NA		NA		NA		NA		NA		NA
IFNA17		NA		NA		NA		NA		NA		NA
IFNA2		NA		NA		NA		NA		NA		NA
IFNA21		NA		NA		NA		NA		NA		NA
IFNA4		NA		NA		NA		NA		NA		NA
IFNA5		NA		NA		NA		NA		NA		NA
IFNA6		NA		NA		NA		NA		NA		NA
IFNA7		NA		NA		NA		NA		NA		NA
IFNA8		NA		NA		NA		NA		NA		NA
IFNAR1	-0.5	7e-06	-0.4	0.003	-0.4	0.1	-0.1	0.7	0.2	0.7	0.0	0.9
IFNAR2	0.4	4e-04	-0.5	0.002	-1.5	0.5	0.9	8e-04	-1.4	0.3	0.5	0.09
IFNB1		NA		NA		NA		NA		NA		NA
IFNG		NA		NA		NA	3.5	0.03	-1.7	0.7	1.9	0.3
IGHA1	3.0	2e-04	-0.3	0.7	0.9	0.5	3.2	0.05	-2.1	0.6	1.0	0.6
IGHA2	2.5	0.05	0.1	1	1.2	0.4	2.3	0.3	-1.5	0.8	0.9	0.7
IGHE		NA		NA		NA		NA		NA		NA
IGHG1	3.4	6e-04	-1.2	0.2	0.8	0.6	4.4	0.04	-2.6	0.6	1.7	0.3
IGHG2	3.0	0.03	-0.6	0.6	0.8	0.7	3.2	0.2	-2.6	0.8	0.8	0.8
IGHG3	3.3	0.008	-0.3	0.8	0.9	0.6	3.4	0.1	-2.8	0.7	0.8	0.7
IGHG4	3.9	0.02	0.7	0.3	1.1	0.4	2.9	0.3	-2.9	0.7	0.1	0.9
IGHM	2.9	0.01	-0.8	0.3	1.7	0.08	3.4	0.1	-1.1	0.9	2.2	0.2
IL17RC	0.5	0.01	0.8	0.02	-0.1	0.9	-0.3	0.2	-0.6	0.3	-0.9	0.05
IL6	4.4	4e-05		NA	5.2	1e-10	3.4	0.04	0.8	0.8	4.2	0.002
IL6R	1.3	4e-07	1.9	2e-07	0.9	0.02	-0.7	0.2	-0.3	0.8	-1.1	0.2
ISG15	2.1	5e-09	0.4	0.2	9.0	3e-22	1.6	0.006	6.9	2e-05	8.5	1e-08
JUN	0.5	0.04	0.4	0.1	0.7	0.07	0.1	0.8	0.2	0.9	0.3	0.5
JUNB	3.1	1e-08	0.7	0.3	3.1	8e-04	2.5	0.007	-0.1	1	2.3	0.01
LTB	2.4	4e-06	0.2	0.7	2.9	6e-05	2.1	0.009	0.5	0.8	2.5	0.01

Gene	ICI-MYO1		ICI-MYO2		ICI-DM		ICI-MYO1		ICI-DM		ICI-DM	
	vs.		vs.		vs.		vs.		vs.		vs.	
	NT	NT	NT	NT	NT	NT	ICI-MYO2	ICI-MYO2	ICI-MYO1	ICI-MYO1	ICI-MYO2	ICI-MYO2
	logFC	adj.P.Val	logFC	adj.P.Val	logFC	adj.P.Val	logFC	adj.P.Val	logFC	adj.P.Val	logFC	adj.P.Val
LTBR	1.2	5e-10	0.7	4e-05	1.1	3e-05	0.5	0.2	-0.1	0.9	0.3	0.2
MAP3K14	0.9	1e-05	1.0	2e-04	0.8	0.04	-0.1	0.8	-0.0	1	-0.2	0.6
MS4A1		NA		NA	2.1	0.02	2.6	0.07	0.9	0.8	3.5	0.04
MT-T1	-2.2	1e-08	-1.5	0.001	-2.7	0.005	-0.7	0.1	-0.4	0.8	-1.1	0.1
MT-TL1	-2.9	5e-17	-2.2	1e-07	-2.8	6e-06	-0.8	0.04	0.2	0.9	-0.6	0.3
MX1	0.7	0.007	-0.6	0.03	7.0	2e-19	1.3	0.02	6.3	2e-05	7.6	4e-08
MYH1	-1.0	0.09	0.3	0.7	-2.9	0.008	-1.3	0.3	-1.8	0.4	-3.2	0.02
MYH3	2.7	5e-07	1.0	0.07	0.8	0.3	1.8	0.07	-1.9	0.3	-0.3	0.8
NCAM1	1.5	3e-06	-0.0	0.9	1.1	0.02	1.5	0.01	-0.4	0.8	1.1	0.05
NFKB1	0.1	0.3	0.3	0.03	0.5	0.003	-0.2	0.4	0.5	0.3	0.2	0.4
NFKB2	1.2	4e-11	0.7	0.004	1.2	1e-04	0.5	0.09	-0.0	1	0.4	0.4
NGF	0.1	0.7	-0.4	0.4	1.9	2e-05	0.5	0.3	1.8	0.02	2.3	0.004
NGFR	2.9	2e-09	0.2	0.8	2.0	0.004	2.7	8e-04	-0.9	0.5	1.7	0.09
NTF3	-0.4	0.1	-0.8	0.04	0.3	0.6	0.2	0.6	0.8	0.4	1.0	0.3
NTF4	-1.4	4e-05	-0.2	0.4	-0.7	0.03	-1.2	0.06	0.8	0.7	-0.5	0.4
PDCD1	5.1	4e-10		NA	4.6	2e-12	3.1	0.006	-0.6	0.8	2.5	0.01
PDCD1LG2	0.3	0.6	-0.9	0.01	1.7	1e-05	1.0	0.2	1.5	0.3	2.5	4e-04
PRF1	2.1	2e-04	0.4	0.3	2.8	1e-06	1.6	0.1	0.7	0.8	2.3	0.008
RELA	0.1	0.1	0.4	7e-04	0.5	0.001	-0.3	0.1	0.4	0.2	0.1	0.8
RELB	1.5	2e-13	1.3	2e-06	1.9	1e-08	0.3	0.4	0.4	0.5	0.6	0.2
SIVA1	-0.2	0.2	0.5	0.02	-0.6	0.05	-0.7	0.02	-0.4	0.4	-1.1	0.01
SOCS3	4.4	2e-11	1.2	0.02	4.5	4e-08	3.3	0.001	-0.0	1	3.3	0.002
STAT3	0.4	4e-05	0.5	5e-04	0.8	5e-04	-0.2	0.4	0.4	0.3	0.2	0.5
TGFB1	1.6	2e-10	-1.0	0.6	0.8	0.01	1.7	4e-04	-0.7	0.4	1.0	0.03
TGFB2	-0.5	0.1	-1.0	0.002	1.2	0.002	0.5	0.4	1.7	0.06	2.2	0.005
TGFB3	0.1	0.8	-0.0	1	1.1	1e-04	0.0	1	1.1	0.3	1.1	0.02
TGFB2	0.9	1e-04	0.1	0.7	0.8	0.06	0.8	0.7	-0.1	0.9	0.6	0.06
TNF	1.5	0.01	-0.5	0.3	1.6	0.008	2.0	0.07	0.0	1	2.0	0.004
TNFRSF10A	1.3	1e-04	0.2	0.6	2.7	2e-10	1.1	0.04	1.4	0.07	2.5	4e-05
TNFRSF10B	1.0	2e-07	0.3	0.2	1.9	1e-09	0.7	0.03	0.9	0.08	1.6	0.002
TNFRSF10C	2.0	3e-05		NA	2.6	2e-04	1.6	0.02	0.5	0.7	2.2	0.02
TNFRSF10D	0.8	0.003	-0.4	0.1	0.1	0.8	1.2	0.03	-0.7	0.6	0.4	0.4
TNFRSF11A	2.0	6e-06	-1.3	0.005	0.7	0.1	3.2	9e-04	-1.2	0.5	2.0	0.02
TNFRSF11B	1.7	2e-04	0.3	0.6	0.3	0.8	1.4	0.02	-1.4	0.3	-0.0	1
TNFRSF12A	2.1	2e-08	1.7	0.001	2.9	1e-04	0.4	0.4	0.7	0.5	1.2	0.06
TNFRSF13B		NA		NA		NA		NA		NA		NA
TNFRSF13C	1.4	2e-08	-0.3	0.4	1.1	0.006	1.8	2e-04	-0.2	0.8	1.5	0.02
TNFRSF14	1.5	5e-07	0.4	0.2	1.6	1e-04	1.1	0.05	0.1	1	1.2	0.08
TNFRSF17		NA		NA		NA		1.6	0.2	0.8	0.8	NA
TNFRSF18	3.1	7e-10		NA	2.2	5e-04	2.8	6e-04	-1.0	0.5	1.8	0.04
TNFRSF19	-0.0	0.9	-1.6	5e-05	-0.6	0.1	1.5	0.008	-0.5	0.6	0.9	0.4
TNFRSF1A	0.8	1e-08	0.5	0.004	0.8	0.001	0.3	0.2	-0.0	1	0.3	0.4
TNFRSF1B	1.5	1e-09	0.3	0.2	1.3	4e-04	1.1	0.008	-0.1	0.9	0.9	0.02
TNFRSF21	1.1	2e-07	0.1	0.8	1.4	2e-06	1.0	0.005	0.4	0.6	1.3	0.006
TNFRSF25	0.6	6e-04	-0.3	0.2	-0.7	0.1	0.9	0.003	-1.2	0.03	-0.4	0.5
TNFRSF4	1.2	0.001	0.8	0.06	2.2	6e-06	0.4	0.6	1.0	0.4	1.4	0.1
TNFRSF6B	0.7	0.3	-2.1	0.1	1.8	0.02	2.9	0.2	1.1	0.7	3.9	0.1
TNFRSF8	1.2	0.001	0.7	0.03	-1.5	0.01	0.4	0.5	-2.6	0.1	-2.2	0.05
TNFRSF9		NA		NA		NA	1.7	0.04	-1.3	0.5	0.4	0.7
TNFSF10	-0.0	1	-0.8	6e-04	1.8	6e-08	0.8	0.2	1.9	0.1	2.6	1e-04
TNFSF11		NA		NA		NA		NA		NA		NA
TNFSF12	0.3	0.07	-0.1	0.7	-0.5	0.06	0.3	0.3	-0.8	0.3	-0.5	0.3
TNFSF13	2.1	7e-11	0.6	0.04	1.0	0.01	1.5	0.002	-1.1	0.3	0.4	0.2
TNFSF13B	2.3	3e-05	-0.4	0.3	3.8	2e-14	2.5	0.02	1.6	0.3	4.1	2e-05
TNFSF14	2.4	1e-05	0.3	0.6	2.0	0.002	2.0	0.02	-0.4	0.9	1.6	0.04
TNFSF15	0.2	0.4	-0.7	0.1	0.7	0.3	0.9	0.03	0.5	0.6	1.3	0.1
TNFSF18		NA		NA	5.3	1e-15		NA	4.0	2e-05	5.7	7e-05
TNFSF4	1.3	2e-05	-0.3	0.5	1.8	3e-04	1.6	0.002	0.5	0.6	2.0	0.01
TNFSF8	1.9	0.01	-0.5	0.4	2.4	1e-05	2.3	0.08	0.5	0.9	2.8	0.002
TNFSF9	1.8	4e-07	-0.2	0.6	1.8	2e-04	2.0	0.001	-0.0	1	2.0	0.005
TYK2	0.3	0.01	0.5	0.002	-0.1	0.8	-0.2	0.3	-0.3	0.6	-0.6	0.04
VCAM1	2.2	2e-07	-0.4	0.3	2.8	5e-09	2.5	0.003	0.7	0.6	3.2	1e-04

